Key statistics
On Friday, Arcutis Biotherapeutics Inc (ARQT:NSQ) closed at 15.01, -15.44% below its 52-week high of 17.75, set on Mar 25, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.24 |
---|---|
High | 15.30 |
Low | 14.70 |
Bid | 15.10 |
Offer | 15.25 |
Previous close | 15.27 |
Average volume | 1.80m |
---|---|
Shares outstanding | 119.20m |
Free float | 114.53m |
P/E (TTM) | -- |
Market cap | 1.82bn USD |
EPS (TTM) | -1.04 USD |
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.
More ▼
- Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
- Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
- Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
- New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
- Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
- Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
- Arcutis Announces Chief Financial Officer Transition
- Arcutis and Padagis Agree to Stay Patent Lawsuit
- Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
- Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
More ▼